Hyperammonaemic encephalopathy associated with rituximab-containing chemotherapy.
Abstract Hyperammonaemic encephalopathy has been infrequently reported after both standard and high-dose chemotherapy for solid and haematological malignancies. It is important to consider this diagnosis for patients with unexplained behaviour changes or encephalopathy and this case report emphasizes this condition and the importance of early diagnosis and is the first reported in association with rituximab-containing chemotherapy.
Nott
L
L
Department of Oncology, The Queen Elizabeth Hospital, Adelaide, Australia.
Price
T J
TJ
Pittman
K
K
Patterson
K
K
Young
R
R
Fletcher
J
J
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects; D001928:Brain Diseases, Metabolic / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis*; D017809:Fatal Outcome; D006801:Humans; D022124:Hyperammonemia / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis*; D008297:Male; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab